de Alencar CR, Carvalho QD, Cuzzi T, Ramos-e-Silva M, Cupertino F

Language: Spanish
References: 11
Page: 210-214
PDF size: 441.38 Kb.

ABSTRACT

Cutaneous lymphoproliferative disorders comprise a heterogeneous group of entities whose diagnosis necessitates a rigorous correlation between clinical presentation, histopathological findings, and ancillary studies. This report presents a case of CD30-positive primary cutaneous T-cell lymphoma, emphasizing the diagnostic challenges, prognostic implications, and the therapeutic limitations associated with this entity.

REFERENCES

1. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary andsecondary cutaneous CD30(+) lymphoproliferative disorders:a report from the Dutch Cutaneous Lymphoma Group on thelong-term follow-up data of 219 patients and guidelines fordiagnosis and treatment. Blood. 2000;95(12):3653-61.

2. Stoll JR, Willner J, Oh Y, et al. Primary cutaneous T-celllymphomas other than mycosis fungoides and Sézarysyndrome. Part I: Clinical and histologic features and diagnosis.J Am Acad Dermatol. 2021;85(5):1073-1090.

3. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of theWHO-EORTC classification for primary cutaneous lymphomas.Blood. 2019;133(16):1703-1714.

4. Willemze R, Kempf WL. Cutaneous T cell lymphoma. In:Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 5ed. ElsevierHealth Sciences; 2024. p. 2156-2176.

5. Chen C, Gu YD, Geskin LJ. A Review of Primary CutaneousCD30+ Lymphoproliferative Disorders. Hematol Oncol ClinNorth Am. 2019;33(1):121-134.

6. Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes ofPatients with Transformed Mycosis Fungoides: Analysis froma Prospective Multicenter US Cohort Study. Clin LymphomaMyeloma Leuk. 2020;20(11):744-748.

7. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes ofpatients with advanced-stage cutaneous T-cell lymphoma andlarge cell transformation. Blood. 2008;112(8):3082-7.

8. O’Donnell M, Zaya R, Correia E, et al. Disease characteristics,prognosis, and response to therapy in patients with large-celltransformed mycosis fungoides: A single-center retrospectivestudy. J Am Acad Dermatol. 2022;86(6):1285-1292.

9. Giordano A, Pagano L. The Treatment of Advanced-Stage MycosisFungoides and Sezary Syndrome: a Hematologist’s Point ofView. Mediterr J Hematol Infect Dis. 2022;14(1):e2022029.

10. Welborn M, Duvic M. Antibody-Based Therapies for CutaneousT-Cell Lymphoma. Am J Clin Dermatol. 2019;20(1):115-122.

11. Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update2021. Hematol Oncol. 2021;39 Suppl 1:46-51.